Clinical spectrum of severe leptospirosis in the UK Open Access

Abstract

Introduction:

Human leptospirosis is a global zoonotic infection with a characteristic biphasic illness and protean clinical manifestations. The majority are mild flu‐like infections. The severe forms cause multiorgan damage with a greater predilection to hepatorenal failure.

Case presentation:

We attempted to analyse the clinical presentation of severe leptospirosis and decipher the clinical spectrum within this group by reviewing a series of 15 patients with leptospirosis requiring intensive care support for their management. We noticed complications becoming apparent before antibodies became detectable in the blood in a significant number of patients. This appears to belie the biphasic nature of leptospirosis and raises the question of whether the complications occur during the leptospiraemic phase or the immune phase of the infection. The presence of leptospiral DNA in the blood at this time as detected by a molecular assay strengthened this suspicion. Among the 15 patients with severe leptospirosis, only 3 (20 %) had an overseas travel history and the remaining 12 patients acquired their infection within the UK. Fourteen of the 15 patients had hepatorenal dysfunction, with seven requiring dialysis. Eight of the 15 patients received intravenous ceftriaxone with very good outcomes. Three showed significant clinical improvement after the administration of steroids.

Conclusion:

Many patients with severe leptospirosis will have complications on presentation. Molecular testing is now available for early diagnosis, facilitating early interventions. Ceftriaxone has been effective in treating severe leptospirosis. This study reminds clinicians to consider leptospirosis in the differential diagnosis of similar clinical spectra and offers tools for appropriate management.

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.000003
2014-12-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/1/4/jmmcr000003.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.000003&mimeType=html&fmt=ahah

References

  1. Bal A.M. ( 2005). Unusual clinical manifestations of leptospirosis. J Postgrad Med 51:179–183
    [Google Scholar]
  2. Dupont H., Dupont‐Perdrizet D., Perie J.L., Zehner‐Hansen S., Jarrige B., Daijardin J.B. ( 1997). Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis 25:720–724 [CrossRef]
    [Google Scholar]
  3. Farr R.W. ( 1995). Leptospirosis. Clin Infect Dis 21:1–8 [CrossRef]
    [Google Scholar]
  4. Gouveia E.L., Metcalfe J., de Carcalho A.L., Aires T.S.T., Villaboas‐Bisneto J.C., Queirroz A., Santos A.C., Salgado K., Reis M.G., Ko A.I. ( 2008). Leptospirosis‐associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis 14:505–508 [CrossRef]
    [Google Scholar]
  5. Ko A.I., Galvao Reis M., Ribeiro Dourado C.M., Johnson W.D., Riley L.W. ( 1999). Urban epidemic of severe leptospirosis in Brazil. Salvador Leptospirosis Study Group. Lancet 354:820–825 [CrossRef]
    [Google Scholar]
  6. Kularatne S.A., Budagoda B.D., de Alwis V.K., Wickramasinghe W.M., Bandara J.M., Pathirage L.P., Gamlath G.R., Wijethunga T.J., Jayalath W.A. other authors( 2011). High efficacy of bolus methylprednisolone in severe leptospirosis: a descriptive study in Sri Lanka. Postgrad Med J 87:13–17 [CrossRef]
    [Google Scholar]
  7. Levett P.N. ( 2001). Leptospirosis. Clin Microbiol Rev 14:296–326 [CrossRef]
    [Google Scholar]
  8. McBride A.J., Athanazio D.A., Reis M.G., Ko A. ( 2005). Leptospirosis. Curr Opin Infect Dis 18:376–386 [CrossRef]
    [Google Scholar]
  9. Meaudre E., Asencio Y., Montcriol A., Martinaud C., Graffin B., Palmier B., Goutorbe P. ( 2008). Immunomodulation in severe leptospirosis with multiple organ failure: plasma exchange, intravenous immunoglobulin or corticosteroids?. Ann Fr Anesth Reanim 27:172–176 [CrossRef]
    [Google Scholar]
  10. Niwattayakul K., Kaewtasi S., Chueasuwanchai S., Hoontrakul S., Chareonwat S., Suttinot C., Phimda K., Chierakul W., Silpasakornand S., Suputtamongkol Y. ( 2010). An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct therapy in patients with pulmonary involvement associated with severe leptospirosis. Clin Microbiol Infect 16:1207–1212 [CrossRef]
    [Google Scholar]
  11. Panaphut T., Domrongkitchaiporn S., Vibhagool A., Thinkamrop B., Susaengrat W. ( 2003). Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis 36:1507–1513 [CrossRef]
    [Google Scholar]
  12. Pappachan M.J., Mathew S., Aravindan K.P., Khader A., Bhargharan P.V., Kareem M.M., Tuteja U., Shukla J., Batra H.V. ( 2004). Risk factors for mortality in patients with leptospirosis during an epidemic in northern Kerala. Natl Med J India 17:240–242
    [Google Scholar]
  13. Shenoy V.V., Nagar V.S., Chowdhury A.A., Bhalgat P.S., Juvale N. ( 2006). Pulmonary leptospirosis: an excellent response to bolus methylprednisolone. Postgrad Med J 82:602–606 [CrossRef]
    [Google Scholar]
  14. Suputtamongkol Y., Niwattayakul K., Suttinont C., Losuwanaluk K., Limpaiboon R., Chierakul W., Wuthiekanun V., Triengrim S., Chenchittikul M., White N.J. ( 2004). An open randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis 39:1417–1424 [CrossRef]
    [Google Scholar]
  15. Trivedi S.V., Chavda R.K., Wadia P.Z., Sheth V., Bhagade P.N., Trivedi S.P., Clerk A.M., Mevawala D.M. ( 2001). The role of glucocorticoid pulse therapy in pulmonary involvement in leptospirosis. J Assoc Physicians India 49:901–903
    [Google Scholar]
  16. Tubiana S., Mikulski M., Becam J., Lacassin F., Lefevre P., Gourinat A‐C., Goarant C., D’Ortenzio E. ( 2013). Risk factors and predictors of severe leptospirosis in New Caledonia. PLoS Negl Trop Dis 7:e1991 [CrossRef]
    [Google Scholar]
  17. Turner L.H. ( 1967). Leptospirosis Leptospirosis I. Trans R Soc Trop Med Hyg 61:842–855 [CrossRef]
    [Google Scholar]
  18. Velissaris D., Karanikolas M., Flaris N., Fligou F., Marangos M., Filos K.S. ( 2012). Commonly used severity scores are not good predictors of mortality in sepsis from severe leptospirosis: a series of ten patients. Crit Care Res Prac 2012:523376
    [Google Scholar]
  19. Vieira S.R., Brauner J.S. ( 2002). Leptospirosis as a cause of acute respiratory failure: clinical features and outcome in 35 critical care patients. Braz J Infect Dis 6:135–139 [CrossRef]
    [Google Scholar]
  20. Zochowski W.J., Palmer M.F., Coleman T.J. ( 2001). An evaluation of three commercial kits for use as screening methods for the detection of leptospiral antibodies in the UK. J Clin Pathol 54:25–30 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.000003
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.000003
Loading

Data & Media loading...

Most cited Most Cited RSS feed